safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: a meta-analysis

Authors

alireza olyaeemanesh national institute for health research, tehran university of medical sciences, tehran, iran.سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences)

mahbobeh rahmani health school department of yazd university of medical sciences, iran.سازمان اصلی تایید شده: دانشگاه یزد (yazd university)

reza goudarzi kerman university of medical sciences, kerman, iran.سازمان اصلی تایید شده: دانشگاه علوم پزشکی کرمان (kerman university of medical sciences)

abulghasem rahimdel shahid sadooghi hospital, yazd university of medical science, yazd, iran.سازمان اصلی تایید شده: دانشگاه یزد (yazd university)

abstract

background: intravenous immunoglobulin (ivig) is an established treatment of immune mediated demyelinating neuropathy including guillain-barré syndrome and chronic inflammatory demyelinating polyneuropathy. recent trials suggest its efficacy in treating relapsing- remitting multiple sclerosis. ivig exerts a number of effects, which may be beneficial in treating multiple sclerosis (ms): reduction of inflammation, inhibition of macrophages, and promotion of remyelination. the aim of this study was to provide an overall assessment of the existing trials of safety and effectiveness of ivig in relapsing- remitting ms compared to other drugs currently available for the treatment of disease activity in ms.   methods: a systematic search strategy was applied to medline (pubmed and ovid medline (1990- nov 2014)), cochrane library 2014, and trip database 2014, crd. the reference lists from the identified trials, ms clinical handbooks and guidelines for the use of ivig were studied. this article was conducted without language restrictions. randomized controlled trials of ivig in ms were selected. sixteen double-blinded trails were randomly selected. ten trials were excluded and we performed a meta-analysis on the six trials (537 participants) of ivig in comparison to placebo. the methodological quality of the trials was assessed using jadad checklist.   results: the meta-analysis showed a significant beneficial effect on proportion of relapse-free patients (or: 1.693; 95% ci-1.205-2.380), on the proportion of patients who improved (or:2.977; 95% ci 1.769-5.010; p=0.0001) and deteriorated (or:0.522; 95% ci0.330-0.827; p=0.006) between placebo and ivig-treated patients. in addition, there was a reduction in the annual relapse rate in the ivig group compared to placebo, which was statistically significant (smd=-0.218; 95% ci-0.412 to -0.024; p=0.028). the results of the meta-analysis did not show significant differences between expanded disability status scale (edss) changes from baseline (smd,-0.025; 95% ci,-0.211 to 0.161; p=0.860).    conclusion: ivig can be considered as an alternative therapeutic option, second-line therapy or adjuvant therapy, considering its beneficial effects (high tolerance, need to be injected with longer intervals, etc.) for treating relapsing–remitting ms patients.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis

Background: Intravenous immunoglobulin (IVIG) is an established treatment of immune mediated demyelinating neuropathy including Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Recent trials suggest its efficacy in treating relapsing- remitting multiple sclerosis. IVIG exerts a number of effects, which may be beneficial in treating multiple sclerosis (MS): R...

full text

Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis

BACKGROUND Intravenous immunoglobulin (IVIG) is an established treatment of immune mediated demyelinating neuropathy including Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Recent trials suggest its efficacy in treating relapsing- remitting multiple sclerosis. IVIG exerts a number of effects, which may be beneficial in treating multiple sclerosis (MS): Reduction...

full text

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.

Intravenous immunoglobulin (IVIG) has several effects on the immune system that could have a beneficial influence on disease processes in multiple sclerosis (MS). Four double-blind trials in relapsing-remitting MS have demonstrated that IVIG may reduce the relapse rate, progression and the number of gadolinium-enhancing lesions. However, these trials were smaller than the pivotal trials of inte...

full text

P120: Efficacy and Safety of Dimethyl Fumarate Treatment in Relapsing-Remitting Multiple Sclerosis

Multiple sclerosis (MS) is a chronic autoimmune disorder of central nervous system. This demyelinating disease affects more than 2.3 million people world wild. Most of patients are young adult. The most common type of MS is relapsing remitting multiple sclerosis (RRMS). However there is no cure, available modifying therapies has revolutionized the care of patients with RRMS. Interferon (IFN) be...

full text

Comparing the Safety and Efficacy of Ziferon and Betaferon in Patients With Remitting-Relapsing Multiple Sclerosis

Background: The present study aimed to compare the clinical efficacy and safety profile of Ziferon and Betaferon. Objectives: In total, 41 consecutive patients with relapsing forms of Multiple Sclerosis (MS) were selected from the MS outpatient clinic affiliated to Tehran University of Medical Sciences. The patients were randomly assigned into two groups. Methods: Each group either received Z...

full text

My Resources

Save resource for easier access later


Journal title:
medical journal of islamic republic of iran

جلد ۳۰، شماره ۱، صفحات ۲۲۵-۲۳۵

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023